TMP-SMX
Selected indexed studies
- The use of trimethoprim and sulfamethoxazole (TMP-SMX) in dermatology. (Folia Med Cracov, 2015) [PMID:26774630]
- TMP-SMX desensitization. (Posit Aware, 1995) [PMID:11362574]
- Pneumocystis jirovecii: a review with a focus on prevention and treatment. (Expert Opin Pharmacother, 2021) [PMID:33870843]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- The use of trimethoprim and sulfamethoxazole (TMP-SMX) in dermatology. (2015) pubmed
- TMP-SMX desensitization. (1995) pubmed
- Pneumocystis jirovecii: a review with a focus on prevention and treatment. (2021) pubmed
- Outcomes associated with trimethoprim/sulphamethoxazole (TMP/SMX) therapy in TMP/SMX resistant community-acquired UTI. (2002) pubmed
- Trimethoprim-sulfamethoxazole. (1999) pubmed
- Antibiotics efficacy in clinical and microbiological cure of uncomplicated urinary tract infection: a systematic review and network meta-analysis. (2024) pubmed
- Comment: TMP/SMX--warfarin interaction. (1989) pubmed
- Comparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV: a systematic review and network meta-analysis of randomized controlled trials. (2025) pubmed
- A Seven-Day Course of TMP-SMX May Be as Effective as a Seven-Day Course of Ciprofloxacin for the Treatment of Pyelonephritis. (2017) pubmed
- Alterations of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics. (2021) pubmed